H.C. Wainwright Maintains Spero Therapeutics(SPRO.US) With Buy Rating, Maintains Target Price $5

Moomoo NewsJan 30 07:31 ET

Spero Therapeutics Analyst Ratings

BenzingaJan 30 06:51 ET

Optimistic Buy Rating for Spero Therapeutics Amid Strategic Initiatives and Partnerships

TipRanksJan 30 06:49 ET

Spero Therapeutics (SPRO) Was Downgraded to a Hold Rating at Evercore ISI

TipRanksDec 22, 2024 19:10 ET

Spero Therapeutics Analyst Ratings

BenzingaDec 20, 2024 06:41 ET

Evercore ISI Group Downgrades Spero Therapeutics to In-Line, Maintains Price Target to $5

BenzingaDec 20, 2024 06:41 ET

Spero Therapeutics Downgraded at Evercore on Lack of Capital Allocation Clarity

TipRanksDec 20, 2024 06:20 ET

H.C. Wainwright Maintains Spero Therapeutics(SPRO.US) With Buy Rating, Maintains Target Price $5

Moomoo NewsDec 2, 2024 06:31 ET

HC Wainwright & Co. Reiterates Buy on Spero Therapeutics, Maintains $5 Price Target

BenzingaDec 2, 2024 06:25 ET

Buy Rating Reiterated for Spero Therapeutics Amid Promising Trial Progress and Strategic Partnership

TipRanksDec 2, 2024 06:23 ET

TD Cowen Initiates Spero Therapeutics(SPRO.US) With Hold Rating

Moomoo NewsNov 19, 2024 03:36 ET

Spero Therapeutics Cut to Hold From Buy by TD Cowen

Dow JonesNov 18, 2024 09:11 ET

TD Cowen Downgrades Spero Therapeutics(SPRO.US) to Hold Rating

Moomoo NewsNov 17, 2024 22:31 ET

Spero Therapeutics Analyst Ratings

BenzingaNov 15, 2024 09:31 ET

H.C. Wainwright Maintains Spero Therapeutics(SPRO.US) With Buy Rating, Cuts Target Price to $5

Moomoo NewsNov 4, 2024 06:33 ET

Spero Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow JonesNov 4, 2024 06:23 ET

Spero Therapeutics Analyst Ratings

BenzingaNov 4, 2024 06:14 ET

TD Cowen Maintains Spero Therapeutics(SPRO.US) With Buy Rating

Moomoo NewsNov 1, 2024 08:31 ET

Spero Therapeutics Analyst Ratings

BenzingaOct 3, 2024 07:50 ET

H.C. Wainwright Maintains Spero Therapeutics(SPRO.US) With Buy Rating, Maintains Target Price $7

Moomoo NewsOct 3, 2024 06:35 ET